866-997-4948(US-Canada Toll Free)

Kidney Fibrosis - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Oncology

No. of Pages : 90 Pages

Kidney Fibrosis - Pipeline Review, H1 2014

Summary

Global Markets Directs, Kidney Fibrosis - Pipeline Review, H1 2014, provides an overview of the Kidney Fibrosiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Kidney Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Kidney Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Kidney Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
n 48
Mechanism of Action 48
R&D Progress 48
CGEN-857 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
cysteamine DR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
INT-767 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PBI-4050 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GR-MD-02 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Anti microRNA-21 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Galectin-3 Inhibitors - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
1D-11 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CT-140 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
BOT-191 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BOT-190 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SOL-1 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
LJ-1888 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
P-529 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ANG-3298 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Kidney Fibrosis - Recent Pipeline Updates 70
Kidney Fibrosis - Dormant Projects 85
Kidney Fibrosis - Product Development Milestones 86
Featured News & Press Releases 86
Jul 05, 2013: Pharmaxis Awarded Two Arc Linkage Grants For Fibrotic Research 86
Nov 01, 2012: Concert Pharma Presents Preclinical Results Of CTP-499 At Kidney Week 2012 86
Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting 87
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 87
Aug 26, 2010: GNI Receives F351 Patent Allowance in Canada 88
Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNIs Key Therapeutic Product for Liver Disease 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 90
Disclaimer 90

List of Table

List of Tables
Number of Products under Development for Kidney Fibrosis, H1 2014 9
Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Kidney Fibrosis - Pipeline by Genzyme Corporation, H1 2014 19
Kidney Fibrosis - Pipeline by BioLineRx, Ltd., H1 2014 20
Kidney Fibrosis - Pipeline by Compugen Ltd., H1 2014 21
Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2014 22
Kidney Fibrosis - Pipeline by Raptor Pharmaceuticals Corp., H1 2014 23
Kidney Fibrosis - Pipeline by Paloma Pharmaceuticals, Inc., H1 2014 24
Kidney Fibrosis - Pipeline by Angion Biomedica Corp., H1 2014 25
Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2014 26
Kidney Fibrosis - Pipeline by GNI Group Ltd., H1 2014 27
Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc., H1 2014 28
Kidney Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2014 29
Kidney Fibrosis - Pipeline by Galectin Therapeutics, H1 2014 30
Kidney Fibrosis - Pipeline by Galecto Biotech AB, H1 2014 31
Kidney Fibrosis - Pipeline by AbbVie Inc., H1 2014 32
Kidney Fibrosis - Pipeline by CisThera Inc., H1 2014 33
Assessment by Monotherapy Products, H1 2014 34
Number of Products by Stage and Target, H1 2014 37
Number of Products by Stage and Mechanism of Action, H1 2014 40
Number of Products by Stage and Route of Administration, H1 2014 42
Number of Products by Stage and Molecule Type, H1 2014 44
Kidney Fibrosis Therapeutics - Recent Pipeline Updates, H1 2014 70
Kidney Fibrosis - Dormant Projects, H1 2014 85

List of Chart

List of Figures
Number of Products under Development for Kidney Fibrosis, H1 2014 9
Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 34
Number of Products by Top 10 Target, H1 2014 35
Number of Products by Stage and Top 10 Target, H1 2014 36
Number of Products by Top 10 Mechanism of Action, H1 2014 38
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 39
Number of Products by Top 10 Route of Administration, H1 2014 41
Number of Products by Stage and Top 10 Route of Administration, H1 2014 42
Number of Products by Top 10 Molecule Type, H1 2014 43
Number of Products by Stage and Top 10 Molecule Type, H1 2014 44

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *